Goldman Sachs tips CSL shares as a buy

CSL Limited (ASX: CSL): Buy, hold, sell?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's often pegged as the best share or company on the S&P/ ASX200 (ASX: XJO) and CSL Limited (ASX: CSL) has many fans among Australia's influential sell side analyst community.

On June 10 2019 the analysts at Goldman Sachs slapped a buy recommendation on CSL shares and $223 12-month share price target on the business. Today the stock changes hands for $224.30 to suggest that if Goldman's analysis is on the money investors won't get much capital growth in the year ahead.

CSL's core business is the sale of blood plasma or immunoglobulin products with Goldman's bullish on the outlook.

"We forecast double digit 3-year CAGRs for both Privigen (+10%) and Hizentra (+13%), driven by improved awareness/diagnosis and a positive shift onto the neurological indication, CIDP. IG represents 65% of our incremental growth forecast to FY21E and whilst IG performance/market conditions remain attractive we believe CSL is well placed to manage other risks in the business," wrote the analysts.

Zooming out a little it's worth noting that CSL sits in the middle of a sweet spot of rising public sector spending on healthcare products around the world.

For example even if the Australian or U.S. governments doubled their annual healthcare spends tomorrow, there would still be political and public demands for even more healthcare spending.

This is a point that over the long term supports great healthcare businesses such as CSL, Cochlear Ltd (ASX: COH) and ResMed Inc. (ASX: RMD).

These three companies are also notable as well because they reinvest a lot of operating cash flow into new products that help them remain market leaders while maintaining profit margins and pricing power.

Profit margins are especially important indicators for investors as to the quality of a healthcare business with rising profit margins a traditional buy signal for analysts, while falling profit margins are a sell signal as they normally represent competitive pressures, downsizing, and more trouble ahead. 

CSL has industry leading margins and widened its EBIT margin from 25% to 30% in FY 2018 in a result that speaks to the strength of the business and explains in a small way why investors are bidding the shares higher. 

Goldman Sachs is forecasting its EBIT margin will grow from 30.9% in FY 2019 to 32.3% in FY 2021, which would be a strong result if achieved. 

Overall then CSL continues to look a good long-term bet for investors, but of course its valuation has run a little hard for now.

Tom Richardson owns shares of Cochlear Ltd., CSL Ltd., and ResMed Inc.

You can find Tom on Twitter @tommyr345

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. and CSL Ltd. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Opinions

2 ASX shares I have been buying in 2024!

I’m a believer in the long-term outlook of these stocks.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »